At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.1: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
29.51BINR318.45M · vs all stocks (USD)
Trailing P/E
79.42xRevenue (TTM)
15.35BINR165.68M · vs all stocks (USD)
Profit Margin
2.41%Beta
0.9180xvs all stocks
52-Week Change
3.49%vs all stocks
Market Capitalization
29.51BINR318.45M · vs all stocks (USD)
Enterprise Value
34.63BINR373.74M · vs all stocks (USD)
Trailing P/E
79.42xForward P/E
19.50xPEG Ratio
1.84xPrice to Sales (TTM)
1.92xPrice to Book (MRQ)
2.05xEnterprise to Revenue
2.26xEnterprise to EBITDA
15.09xGross Margin
48.52%Profit Margin
2.41%Operating Margin
12.03%Return on Assets (TTM)
3.42%Return on Equity (TTM)
2.74%Revenue (TTM)
15.35BINR165.68M · vs all stocks (USD)
Revenue per Share (TTM)
332.11INRUpdated Oct 25, 2026Quarterly Revenue Growth
33.10%Gross Profit (TTM)
6.93BINR74.74M · vs all stocks (USD)
EBITDA (TTM)
2.00BINR21.54M · vs all stocks (USD)
Net Income (TTM)
369.40MINR3.99M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.57%Operating Cash Flow (TTM)
1.42BINR15.35M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-436.96MINR-4.72M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
26.70MINRFY2026 · Mar 31, 2026Revenue
13.30BINRFY2026 · Mar 31, 2026Cost of Goods Sold
7.08BINRFY2026 · Mar 31, 2026Gross Profit
6.22BINRFY2026 · Mar 31, 2026Operating Income
878.90MINR9.49M · vs all stocks (USD)
Pre-tax Income
-74.10MINRFY2026 · Mar 31, 2026Income Tax Expense
0.00INRFY2026 · Mar 31, 2026Net Income
-74.10MINRFY2026 · Mar 31, 2026EBIT
694.50MINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
1.75BINRFY2026 · Mar 31, 2026Selling, General & Administrative
540.20MINRFY2026 · Mar 31, 2026Other Operating Expenses
1.98BINRFY2026 · Mar 31, 2026Non-operating Interest Income
13.70MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
768.60MINRFY2026 · Mar 31, 2026EPS (Basic)
-1.68INRFY2026 · Mar 31, 2026EPS (Diluted)
-1.68INRFY2026 · Mar 31, 2026Basic Shares Outstanding
44.04MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
44.04MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-74.10MINRFY2026 · Mar 31, 2026Minority Interests (P&L)
0.00INRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
250.10MINRFY2026 · Mar 31, 2026Free Cash Flow
245.00MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
44.80MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-74.10MINRFY2026 · Mar 31, 2026Stock-based Compensation
46.70MINRFY2026 · Mar 31, 2026Other Non-cash Items
918.20MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.11BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
472.50MINRFY2026 · Mar 31, 2026Capital Expenditures
5.10MINRFY2026 · Mar 31, 2026Net Acquisitions
800.00KINRFY2026 · Mar 31, 2026Purchase of Investments
-487.00MINRFY2026 · Mar 31, 2026Other Investing Activity
10.70MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-470.40MINRFY2026 · Mar 31, 2026Long-term Debt Issuance
495.00MINRFY2026 · Mar 31, 2026Long-term Debt Payments
-888.90MINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-768.10MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
423.20MINRFY2026 · Mar 31, 2026Shares Outstanding
48.08MSharesUpdated Oct 25, 2026Float Shares
33.12MSharesUpdated Oct 25, 2026% Held by Insiders
52.23%vs all stocks
% Held by Institutions
16.64%vs all stocks
Total Cash (MRQ)
709.10MINR7.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
14.75INRUpdated Oct 25, 2026Total Debt (MRQ)
5.91BINR63.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4110xCurrent Ratio (MRQ)
1.32xBook Value per Share (MRQ)
298.72INRUpdated Oct 25, 2026Total Assets
23.33BINR251.73M · vs all stocks (USD)
Total Current Assets
8.58BINRFY2026 · Mar 31, 2026Total Liabilities
10.77BINRFY2026 · Mar 31, 2026Total Non-current Assets
14.74BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
1.83BINRFY2026 · Mar 31, 2026Total Current Liabilities
8.94BINRFY2026 · Mar 31, 2026Cash
33.50MINRFY2026 · Mar 31, 2026Cash Equivalents
11.30MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
44.80MINRFY2026 · Mar 31, 2026Other Short-term Investments
487.00MINRFY2026 · Mar 31, 2026Accounts Receivable
4.39BINRFY2026 · Mar 31, 2026Inventory
3.18BINRFY2026 · Mar 31, 2026Accounts Payable
2.74BINRFY2026 · Mar 31, 2026Short-term Debt
5.57BINRFY2026 · Mar 31, 2026Other Current Liabilities
47.00MINRFY2026 · Mar 31, 2026Long-term Debt
1.30BINRFY2026 · Mar 31, 2026Common Stock (Book)
445.10MINRFY2026 · Mar 31, 2026Retained Earnings
-3.19BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
12.56BINR135.50M · vs all stocks (USD)
52-Week Low
422.00INRUpdated Oct 25, 202652-Week High
774.00INRUpdated Oct 25, 202652-Week Change
3.49%vs all stocks
Beta
0.9180xvs all stocks
50-Day MA
670.27INRUpdated Oct 25, 2026200-Day MA
552.14INRUpdated Oct 25, 2026Avg 10-Day Volume
946.81KSharesUpdated Oct 25, 2026Avg 30-Day Volume
603.49KSharesUpdated Oct 25, 2026Diluted EPS (TTM)
7.71INRUpdated Oct 25, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.49Profit Margin: 0.02
Financial Health
Altman Z-Score 2.1: grey zoneSignificant
Altman Z-Score: 2.10
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule